Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects

Bristol-Myers Squibb60 个研究点分布在 5 个国家开始时间: 1999年12月最近更新: 2011年5月4日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
试验地点: 60

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.

详细描述

This is a three-arm study; patients are randomized to receive BMS-232632 at two different doses or RTV in combination with SQV and two nucleoside analogues over 48 weeks. Randomization is stratified for baseline phenotypic sensitivity.

研究设计

研究类型: Interventional
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

研究点 (60)

Loading locations...

相似试验

已完成

1 期

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNAHIV Infections

NCT03181789National Institute of Allergy and Infectious Diseases (NIAID)56

已完成

1 期

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected AdultsHIV Infections

NCT01095224National Institute of Allergy and Infectious Diseases (NIAID)180

已完成

1 期

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected AdultsHIV Infections

NCT00115960National Institute of Allergy and Infectious Diseases (NIAID)120

已完成

1 期

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV PatientsHIV-1 Infections

NCT01013415University of Pennsylvania17

Unknown

1 期

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected AdultsHIV Infections

NCT00061243National Institute of Allergy and Infectious Diseases (NIAID)36